PROTAC BTK Degrader Conjugation for Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BTK inhibitors are not potent enough and lack alternative strategies for degrading Bruton's tyrosine kinase (BTK), which is crucial for treating autoimmune and inflammatory diseases, as well as cancer.
Innovation Solution
Development of proteolysis targeting chimera (PROTAC) compounds that conjugate a BTK inhibitor with an E3 ligase ligand to recruit targeted proteins to E3 ubiquitin ligase for degradation, specifically designed to inhibit BTK activity through targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional BTK inhibitors are used, then BTK activity is inhibited, but the inhibitors are not potent enough and resistance develops
Solution Approach 1:
The patent extracts the target protein (BTK) from the cell and destroys it through proteasome-mediated degradation, rather than merely inhibiting its activity. The PROTAC compound removes BTK from the cellular environment and directs it to the proteasome for complete degradation, eliminating the source of resistance and providing superior potency compared to conventional inhibitors that merely block BTK activity.
Solution Approach 2:
The patent converts the harmful persistent presence of BTK (which causes disease and treatment resistance) into a beneficial process by utilizing the cell's own ubiquitin-proteasome system. The PROTAC compound hijacks this natural degradation pathway to selectively destroy BTK, transforming a potentially harmful protein into a target for controlled destruction, thereby eliminating resistance mechanisms.
2Reliability
If PROTAC compounds are designed to degrade BTK, then treatment potency is improved, but the molecular structure and mechanism become more complex
Solution Approach 1:
The PROTAC compound is segmented into three distinct functional moieties: a BTK-binding portion (first moiety), a linker (second moiety), and an E3 ligase ligand (third moiety). This segmentation allows each component to be optimized independently - the first moiety for high-affinity BTK binding, the linker for proper spatial arrangement, and the third moiety for E3 ligase recruitment - thereby achieving high treatment potency while maintaining manageable structural complexity through modular design.
Solution Approach 2:
The linker acts as an intermediary element that bridges the BTK-binding portion and the E3 ligase ligand. This intermediary structure is crucial for maintaining the proper spatial relationship between the two functional moieties, allowing the PROTAC to effectively recruit BTK to the proteasome. The linker's carefully designed structure enables this mediation while keeping the overall molecular architecture manageable.
3Adaptability or versatility
If existing BTK inhibitors are used, then treatment is provided, but they do not offer alternative strategies for degrading BTK
Solution Approach 1:
Instead of using conventional inhibitors that bind to and block BTK's active site (the traditional approach), the patent inverts the strategy by using a PROTAC compound that recruits BTK for degradation. This inversion of the mechanism - from inhibition to degradation - provides a completely alternative treatment strategy that overcomes resistance to existing inhibitors by eliminating BTK rather than blocking its activity.
Solution Approach 2:
The PROTAC compound serves multiple functions simultaneously: it binds to BTK, recruits BTK to the E3 ligase, and facilitates BTK degradation. This multi-functionality consolidates several actions into a single molecular entity, providing a versatile treatment approach that can overcome resistance mechanisms while maintaining effectiveness against BTK-positive diseases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAC compounds effectively inhibit BTK activity, offering a potent and alternative strategy for treating autoimmune and inflammatory diseases, as well as cancer by degrading BTK, potentially overcoming resistance to existing treatments.
Implementation Method 1
Ubiquitin, which is highly conserved in eukaryotic cells, is a modifier molecule, composed of 76 amino acids, that covalently binds to and labels target substrates via a cascade of enzymatic reactions involving E1, E2, and E3 enzymes. Subsequently, the modified substrate is recognized by the 26S proteasome complex for ubiquitination-mediated degradation.
Data Source
AI summary
Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.